Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABSW) Return on Equity (2021 - 2025)

Historic Return on Equity for SAB Biotherapeutics (SABSW) over the last 5 years, with Q3 2025 value amounting to 0.48%.

  • SAB Biotherapeutics' Return on Equity rose 6200.0% to 0.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.48%, marking a year-over-year increase of 6200.0%. This contributed to the annual value of 1.01% for FY2024, which is 500.0% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported Return on Equity of 0.48% as of Q3 2025, which was up 6200.0% from 2.44% recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Return on Equity high stood at 0.15% for Q3 2021, and its period low was 2.44% during Q2 2025.
  • Its 5-year average for Return on Equity is 0.94%, with a median of 0.82% in 2024.
  • The largest annual percentage gain for SAB Biotherapeutics' Return on Equity in the last 5 years was 6200bps (2025), contrasted with its biggest fall of -16300bps (2025).
  • Over the past 5 years, SAB Biotherapeutics' Return on Equity (Quarter) stood at 0.47% in 2021, then plummeted by -30bps to 0.61% in 2022, then plummeted by -92bps to 1.16% in 2023, then rose by 11bps to 1.04% in 2024, then surged by 54bps to 0.48% in 2025.
  • Its Return on Equity was 0.48% in Q3 2025, compared to 2.44% in Q2 2025 and 1.62% in Q1 2025.